Subscribe

Recent Articles

Popular Posts

Site search

Follow Us

Biotech Companies Testing the Open Source Model

Written by on Thursday, February 22nd, 2007 Print This Post Print This Post

In case you missed it, Matthew Herper and Robert Langreth wrote in a recent Forbes.com article about an interesting new trend in the biotech industry–applying the open source model to the biotech world.

Herper and Langreth reported as follows:

Novartis. . . the Basel, Switzerland, drug giant, has helped uncover which of the 20,000 genes identified by the Human Genome Project are likely to be associated with diabetes. But rather than hoard this information, as drug firms have traditionally done, it is making it available for free on the World Wide Web. . . .Researchers at Novartis partnered with Sweden’s Lund University and the Cambridge, Mass.-based Broad Institute, a joint venture between the Massachusetts Institute of Technology and Harvard that is funded by billionaire Eli Broad. This international team compared the genomes of 1,500 people who had diabetes with 1,500 who were disease-free. All the patients were from Sweden. To do this quickly, the scientists used gene chips from biotech Affymetrix. . . that allowed them to track 500,000 places in the genetic code where past experience has shown that there are likely to be differences.

The result: a library of genetic differences that are likely to increase a patient’s risk of diabetes. Researchers don’t know what most of these errant genes do, or exactly why diabetics are more likely to have these genes. That is exactly the puzzle a world’s worth of scientists are needed to unravel. . . .

It is inevitable that the biotech world would begin to test the open source model, which has become so popular in the software industry, but it raises some interesting questions about how best to adapt the model from software to biotechnology.  What should such a license look like? Will the biotech community embrace such a model the same way that the software engineering world has?  Is biotech likely to run into the same problems with an open source model that the software world has?

It will be interesting to watch this new trend to see if it takes off, and if so, what it ends up meaning for the industry.

 

 

 

887 total views, 1 views today


© 2008-2015 The Prinz Law Office. All rights reserved.

The Prinz Law Office | Silicon Valley, CA | Los Angeles, CA | Orange County, CA | San Diego, CA | Atlanta, GA | Tel: 1.800.884.2124

Mailing Address: 117 Bernal Rd., Suite 70-110, San Jose, CA 95119; Silicon Valley Office: San Jose- 2033 Gateway Place, 5th Floor, San Jose, CA 95110 (408)884-2854; Los Angeles Office: 3110 Main St., Building C, Santa Monica, CA 90405 (310)907-9218; Orange County Office: 100 Spectrum Center Drive, 9th Floor, Irvine, CA 92618 (949)236-6777; San Diego Office: 4455 Murphy Canyon Road, Suite 100, San Diego, CA 92123 (619)354-2727 Atlanta Office: 1000 Parkwood Circle, Suite 900, Atlanta, Georgia 30339 (404)479-2470

Biotech Lawyer & Attorney: Serving Silicon Valley, San Jose, San Francisco, Santa Cruz, San Diego, Los Angeles, Orange County, Irvine, Anaheim, Santa Monica, Silicon Beach, Santa Barbara, Sacramento, Atlanta. Licensed in California and Georgia.
Follow

Get every new post delivered to your Inbox

Join other followers